Jack Bendheim Sells 3,651 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 3,651 shares of the company’s stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03. Following the completion of the transaction, the chief executive officer owned 47,457 shares in the company, valued at $1,923,432.21. This represents a 7.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total transaction of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total transaction of $232,425.60.

Phibro Animal Health Stock Up 0.5%

Shares of PAHC traded up $0.19 during mid-day trading on Thursday, hitting $40.06. The company’s stock had a trading volume of 176,958 shares, compared to its average volume of 194,706. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32. The company’s 50-day moving average is $40.70 and its 200-day moving average is $36.90. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 1.14 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.15. The company had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is presently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

A number of large investors have recently modified their holdings of PAHC. Financial Management Professionals Inc. acquired a new position in shares of Phibro Animal Health during the second quarter valued at about $32,000. Hughes Financial Services LLC purchased a new stake in Phibro Animal Health during the 3rd quarter worth approximately $40,000. iSAM Funds UK Ltd purchased a new stake in Phibro Animal Health during the 3rd quarter worth approximately $61,000. EverSource Wealth Advisors LLC increased its stake in Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of Phibro Animal Health in the third quarter worth $96,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. lifted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.